Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$32.86

-0.19 (-0.57%)

, AGN

Allergan

$230.31

-0.49 (-0.21%)

06:58
10/03/16
10/03
06:58
10/03/16
06:58

AstraZeneca out-licenses potential inflammatory diseases medicine to Allergan

AstraZeneca (AZN) announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Allergan (AGN) for the global rights to MEDI2070. MEDI2070 is an IL-23 monoclonal antibody currently in a Phase IIb clinical trial for moderate-to-severe Crohn's disease and is ready for Phase II for ulcerative colitis. These diseases are outside AstraZeneca's three main therapy areas - Respiratory, Cardiovascular & Metabolic Diseases, and Oncology. MedImmune will continue the ongoing Phase II trials until a mutually-agreed transition date. Under the terms of the agreement, Allergan will make an upfront payment to AstraZeneca of $250M for the exclusive, worldwide licence to develop and commercialise MEDI2070. In addition, Allergan may make potential additional payments to AstraZeneca of up to $1.27B, dependent on the achievement of agreed upon success-based development and sales-related milestones, and pay tiered royalties on potential sales of the medicine. MedImmune has been leading the clinical development for MEDI2070 under a collaboration agreement AstraZeneca entered into with Amgen (AMGN) in March 2012. Under the conditions of this agreement, AstraZeneca will subsequently pay Amgen one third of all payments and royalties received from Allergan. Amgen will also receive a single-digit percentage inventor royalty on MEDI2070.

AZN

AstraZeneca

$32.86

-0.19 (-0.57%)

AGN

Allergan

$230.31

-0.49 (-0.21%)

AMGN

Amgen

$166.81

1.36 (0.82%)

  • 07

    Oct

  • 05

    Nov

  • 06

    Nov

  • 16

    Nov

  • 19

    Jul

AZN AstraZeneca
$32.86

-0.19 (-0.57%)

09/23/16
PIPR
09/23/16
INITIATION
PIPR
Overweight
AstraZeneca initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started AstraZeneca with an Overweight rating and GBP 60 price target.
09/12/16
09/12/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pandora (P) upgraded to Buy from Neutral at SunTrust with analyst Robert Peck saying he thinks that a new interactive offering by the company could raise its contribution profit by 4%-9% and that the Street's 2017 estimates for the company "seem conservative." The analyst added that he thinks it's "very possible" that Pandora will be acquired. 2. AstraZeneca (AZN) upgraded to Buy from Hold at Jefferies with analyst Jeffrey Holford saying the company's MYSTIC oncology study could drive 39% share upside if successful. 3. Apache (APA) and upgraded to Overweight from Neutral at Atlantic Equities and to Peer Perform from Underperform at Wolfe Research. 4. Philip Morris (PM) upgraded to Conviction Buy from Neutral at Goldman with analyst Judy Hong saying she is increasingly bullish on the prospects of Next Generation Products and expects them to contribute 5%-6% of earnings by 2020. 5. Wal-Mart (WMT) upgraded to Outperform from Market Perform at Cowen with analysts led by Oliver Chen saying price investments, integration of physical and digital, and the Jet acquisitions position the company to regain its dominance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/13/16
EXAN
09/13/16
DOWNGRADE
EXAN
Neutral
AstraZeneca downgraded to Neutral from Outperform at Exane BNP Paribas
09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AGN Allergan
$230.31

-0.49 (-0.21%)

09/22/16
BERN
09/22/16
NO CHANGE
BERN
Allergan acquisitions positive, says Bernstein
After Allergan bought two companies with NASH drugs and the stock fell, Bernstein analyst Aaron Gal says the acquisitions were viewed as expensive. Gal says "it makes almost no difference" if the deals were expensive, as the important issue is whether the products succeed. He believes that the market would never penalize Roche or Celgene for similar deals, and he thinks this indicates that Allergan is "misvalued." He says that Allergan is his "high conviction buy" stock and keeps a $335 price target on the shares.
09/26/16
LEER
09/26/16
NO CHANGE
LEER
Shire Xiidra launch to 'significantly' expand dry eye category, says Leerink
Leerink analyst Jason Gerberry remains optimistic that Shire's (SHPG) Xiidra launch will "significantly" expand the category for dry eye disease brands, while not meaningfully eroding Allergan's (AGN) Restasis market leading position. While it's still early in the launch of Xiidra and payer access remains a critical variable, the analyst does not anticipate access being a major barrier. Gerberry reiterates an Outperform rating on both Shire and Allergan's shares.
09/21/16
GABE
09/21/16
NO CHANGE
GABE
Buy
Gabelli questions if Allergan could target Gilead next
Gabelli analyst Kevin Kedra said that "like most" he was surprised at the price paid and the strategic fit of Allergan's (AGN) deal to buy Tobira Therapeutics (TBRA), but wonders if Allergan CEO Brent Saunders is "playing chess while the market is playing checkers" and could be preparing a bid for Gilead (GILD). After Allergan's "very loud statement about its commitment to NASH and liver disease," a deal for Gilead, the leading company in liver disease and "one of the cheapest companies in pharma/biotech," would appear to make more sense, Kedra tells investors, adding that an acquisition of Gilead at a price of $115 per share would be "highly accretive" for Allergan. The analyst keeps a Buy rating on Allergan shares.
09/21/16
CANT
09/21/16
DOWNGRADE
CANT
Hold
Tobira Therapeutics downgraded to Hold from Buy at Cantor
Cantor analyst Elemer Piros downgraded Tobira (TBRA) after the company agreed to be acquired by Allergan (AGN). Target to $42 from $19.
AMGN Amgen
$166.81

1.36 (0.82%)

09/27/16
PIPR
09/27/16
NO CHANGE
PIPR
Overweight
Amgen's Kyprolis in good shape despite trial miss, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says Amgen's Kyprolis is still likely to be viewed as a "potent backbone, with the right drugs" after a Phase 3 study in front-line myeloma failed to reach its primary endpoint. The analyst believes the impact of the failed trial on Kyprolis use will be limited and he reiterates an Overweight rating on Amgen.
09/27/16
GSCO
09/27/16
NO CHANGE
Target $206
GSCO
Conviction Buy
Goldman surprised by Amgen's Kyprolis outcome in first-line multiple myeloma
Last night, Amgen announced Phase 3 Kypolis CLARION study did not meet the primary endpoint in first-line multiple myeloma. Goldman analyst Terence Flynn was surprised by this outcome given the prior positive superiority data for Kyprolis versus Velcade in the Phase III ENDEAVOR trial. Flynn sees risk to his Kyprolis $1B sales estimate in a first-line setting, but awaits for additional details from the call and further information regarding another ongoing Phase III trial. He expects Amgen shares to be weak on the news but said the company has additional drivers beyond Kyprolis including Repatha for high cholesterol and Erenumab for migraine with additional data expected in 2H 2016 and Q1 2017. Flynn remains Conviction Buy rated on Amgen and maintains his $206 price target.
09/01/16
09/01/16
NO CHANGE

Amgen's sBLA for Blincyto approved by FDA
Amgen's supplemental Biologics License Application for Blincyto has been approved by the FDA to include new data supporting the treatment of pediatric patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This indication is approved under accelerated approval, and continued approval may be contingent upon verification of clinical benefit in subsequent trials. The approval is based on results from the Phase 1/2 '205, an open-label, multicenter, single-arm trial, which evaluated the efficacy and safety of BLINCYTO in pediatric patients with relapsed or refractory B-cell precursor ALL. Blincyto was granted breakthrough therapy, priority review and orphan drug designations by FDA, and is now approved in the U.S. for the treatment of Ph- relapsed or refractory B-cell precursor ALL. In November 2015, BLINCYTO was granted conditional marketing authorization in the European Union for the treatment of adults with Ph- relapsed or refractory B-cell precursor ALL.
09/29/16
PIPR
09/29/16
NO CHANGE
Target $10
PIPR
Overweight
Arrowhead price target raised to $10 from $8 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals (ARWR) to $10 after the company licensed two preclinical cardiovascular RNAi drugs with Amgen (AMGN). Amgen is the "ideal partner" and Arrowhead's balance sheet is now "meaningfully" strengthened, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Arrowhead.

TODAY'S FREE FLY STORIES

DVN

Devon Energy

$31.17

0.69 (2.26%)

13:30
06/26/17
06/26
13:30
06/26/17
13:30
Options
Devon Energy draws a bullish longer-term option play »

Devon Energy draws a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

DAL

Delta Air Lines

$52.94

0.02 (0.04%)

13:26
06/26/17
06/26
13:26
06/26/17
13:26
Periodicals
Amtrak picks former Delta CEO Anderson as new CEO, WSJ reports »

Former Delta CEO Richard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 30

    Jun

  • 07

    Jul

13:25
06/26/17
06/26
13:25
06/26/17
13:25
General news
Treasury Action: shorter yields dipped slightly after the strong 2-year sale »

Treasury Action: shorter…

PDCE

PDC Energy

$44.72

2.21 (5.20%)

13:22
06/26/17
06/26
13:22
06/26/17
13:22
Hot Stocks
Department of Justice, Colorado file civil complaint against PDC Energy »

The Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

FOXA

21st Century Fox

$27.19

0.22 (0.82%)

13:20
06/26/17
06/26
13:20
06/26/17
13:20
Options
Call buyer opens a notable new position in 20th Century Fox »

Call buyer opens a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$155.07

1.67 (1.09%)

, MSFT

Microsoft

$71.21

0.95 (1.35%)

13:19
06/26/17
06/26
13:19
06/26/17
13:19
Hot Stocks
Facebook, Twitter, Microsoft, YouTube form global forum to counter terrorism »

Facebook (FB), Microsoft…

FB

Facebook

$155.07

1.67 (1.09%)

MSFT

Microsoft

$71.21

0.95 (1.35%)

TWTR

Twitter

$18.35

-0.155 (-0.84%)

GOOG

Alphabet

$965.59

8.5 (0.89%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

  • 20

    Jul

$NSD

NASDAQ Market Internals

13:17
06/26/17
06/26
13:17
06/26/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
06/26/17
06/26
13:16
06/26/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$56.22

-0.08 (-0.14%)

, SPY

SPDR S&P 500 ETF Trust

$243.72

0.59 (0.24%)

13:15
06/26/17
06/26
13:15
06/26/17
13:15
Technical Analysis
Technical View: S&P 500 chart view at mid-session »

The small bearish price…

XLK

Technology Select Sector SPDR

$56.22

-0.08 (-0.14%)

SPY

SPDR S&P 500 ETF Trust

$243.72

0.59 (0.24%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GG

Goldcorp

$13.68

-0.12 (-0.87%)

13:15
06/26/17
06/26
13:15
06/26/17
13:15
Options
Goldcorp put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

KR

Kroger

$22.58

-0.02 (-0.09%)

13:15
06/26/17
06/26
13:15
06/26/17
13:15
Hot Stocks
Kroger executive VP Schlotman acquires 2,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
06/26/17
06/26
13:15
06/26/17
13:15
General news
Treasury's $26 B 2-year sale was well received, as expected »

Treasury's $26 B…

DB

Deutsche Bank

$16.89

0.25 (1.50%)

13:12
06/26/17
06/26
13:12
06/26/17
13:12
Periodicals
Deutsche Bank's chief U.S. economist LaVorgna steps down, Bloomberg reports »

Joe LaVorgna, a chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

WDC

Western Digital

$93.34

3.09 (3.42%)

, TOSYY

Toshiba, also use TOSBF

$15.98

-1.415 (-8.14%)

13:11
06/26/17
06/26
13:11
06/26/17
13:11
Periodicals
Toshiba near sale of memory chip unit to consortium, Nikkei reports »

Toshiba (TOSYY) could…

WDC

Western Digital

$93.34

3.09 (3.42%)

TOSYY

Toshiba, also use TOSBF

$15.98

-1.415 (-8.14%)

TOSBF

Toshiba, also use TOSYY

$2.66

-0.22 (-7.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$146.28

0.65 (0.45%)

13:09
06/26/17
06/26
13:09
06/26/17
13:09
Hot Stocks
Apple CEO: 'Inspired' by Indian PM Modi's vision »

Following a meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

ZIXI

ZixCorp

$5.77

-0.06 (-1.03%)

13:05
06/26/17
06/26
13:05
06/26/17
13:05
Hot Stocks
Breaking Hot Stocks news story on ZixCorp »

ETF Managers reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RETA

Reata Pharmaceuticals

$28.97

-0.29 (-0.99%)

12:58
06/26/17
06/26
12:58
06/26/17
12:58
Hot Stocks
Breaking Hot Stocks news story on Reata Pharmaceuticals »

Novo Holdings cuts Reata…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

HSTM

HealthStream

$30.89

0.72 (2.39%)

12:57
06/26/17
06/26
12:57
06/26/17
12:57
Recommendations
HealthStream analyst commentary  »

HealthStream contract end…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

12:55
06/26/17
06/26
12:55
06/26/17
12:55
General news
Treasury 2-year auction preview: the sale should see decent results »

Treasury 2-year auction…

12:55
06/26/17
06/26
12:55
06/26/17
12:55
General news
Breaking General news story  »

San Francisco Federal…

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

12:46
06/26/17
06/26
12:46
06/26/17
12:46
Hot Stocks
Amazon CEO: Excited to keep investing in India »

Following a meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 26

    Jun

  • 28

    Jun

GOOG

Alphabet

$965.59

8.5 (0.89%)

, GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

12:43
06/26/17
06/26
12:43
06/26/17
12:43
Periodicals
EU to likely hit Google with record fine in antitrust case, Reuters says »

EU antitrust authorities…

GOOG

Alphabet

$965.59

8.5 (0.89%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

NURO

NeuroMetrix

$2.95

0.06 (2.08%)

12:39
06/26/17
06/26
12:39
06/26/17
12:39
Hot Stocks
NeuroMetrix names Xuan Kong as Chief Data Scientist »

NeuroMetrix provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$17.41

-0.13 (-0.74%)

12:38
06/26/17
06/26
12:38
06/26/17
12:38
Periodicals
Snap taps Internet Association's Woodworth for public policy team, Recode says »

Recode's Tony Romm…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 19

    Jul

DEO

Diageo

$120.05

0.7915 (0.66%)

12:36
06/26/17
06/26
12:36
06/26/17
12:36
Upgrade
Diageo rating change  »

Diageo upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.